#USA #Deerfield #Baxter #Hemopatch #collagen pad

Introduction to HEMOPATCH

Baxter International Inc. has made a significant advancement in medical technology with the launch of HEMOPATCH, a novel hemostatic sealant that stands out due to its innovative design for room-temperature storage. This new variant has the potential to transform surgical practices by dramatically improving the efficiency and effectiveness of wound management. Announced on May 20, 2025, by Baxter's advanced surgical president Steve Wallace, HEMOPATCH marks a milestone for the company in terms of innovation and patient care.

What is HEMOPATCH?

HEMOPATCH is a collagen-based hemostatic agent that acts to rapidly control bleeding and seal wounds, making it suitable for both open surgeries and minimally invasive procedures. One of the standout features of HEMOPATCH is its extended shelf-life of three years, allowing healthcare providers to have versatile and effective options readily available without stringent storage requirements. The hemostatic action occurs through a synergistic interaction of two components that rapidly induces lasting hemostasis while sealing the surface of bleeding wounds.

How HEMOPATCH Works

The unique mechanism of HEMOPATCH is based on its hydrogel-forming properties. The white side that adheres to the wound is covered with a thin layer of NHS-PEG (N-hydroxysuccinimide-polyethylene glycol). Upon contact with blood or other bodily fluids, NHS-PEG transforms into a hydrogel, which enhances the adhesive properties of the hemostatic agent while effectively sealing the wound surface. The collagen within the patch attracts platelets, resulting in a rapid aggregation of these crucial components at the site of injury. As platelets degranulate, they release clotting factors that, in combination with plasma factors, facilitate the formation of fibrin, essential for wound healing.

Clinical Benefits

HEMOPATCH is designed to provide swift and efficient hemostasis within just two minutes, allowing for timely surgical interventions. Its three-dimensional matrix structure effectively absorbs fluids and reinforces the mechanical stability of the clot. Preclinical studies have indicated that the resorption and replacement with the patient’s own tissue occur approximately six to eight weeks post-application, with minimal tissue reaction. The clinical advantages of HEMOPATCH include:

• - Effective sealing of tissues
• - Prevention and control of leaks
• - Rapid and effective hemostatic response
• - Biocompatibility and gradual resorption

Indications and Use

HEMOPATCH is indicated for use in various surgical settings, and its design focuses on enhancing the safety and efficacy of surgical interventions. However, it's essential for practitioners to consult the video material associated with this article and the official website for risk factors and proper application guidelines.

Conclusion

As Baxter continues to innovate in the field of surgical technology, HEMOPATCH represents a pivotal advancement in controlling blood loss and managing surgical wounds. The ease of room-temperature storage, paired with its effective performance, positions HEMOPATCH as a promising solution for modern surgical practices. For further information, visit Baxter’s official page.

Note for Medical Professionals

This announcement is primarily intended for medical professionals and should not be interpreted as medical advice. Please contact qualified healthcare providers for any health concerns. HEMOPATCH is approved for use only in select countries. For information regarding availability and regulatory status, consult your local Baxter Healthcare representative.